Vestmark Advisory Solutions Inc. Sells 13,110 Shares of DexCom, Inc. (NASDAQ:DXCM)

Vestmark Advisory Solutions Inc. lessened its stake in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 67.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,452 shares of the medical device company’s stock after selling 13,110 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in DexCom were worth $520,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Centaurus Financial Inc. lifted its holdings in DexCom by 5.5% during the first quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after acquiring an additional 64 shares during the period. Jaffetilchin Investment Partners LLC lifted its holdings in DexCom by 7.7% during the first quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock worth $440,000 after acquiring an additional 101 shares during the period. Worth Venture Partners LLC lifted its holdings in DexCom by 26.4% during the first quarter. Worth Venture Partners LLC now owns 594 shares of the medical device company’s stock worth $304,000 after acquiring an additional 124 shares during the period. Founders Financial Securities LLC increased its position in DexCom by 26.0% in the first quarter. Founders Financial Securities LLC now owns 621 shares of the medical device company’s stock worth $318,000 after buying an additional 128 shares during the last quarter. Finally, Lido Advisors LLC increased its position in DexCom by 10.2% in the first quarter. Lido Advisors LLC now owns 1,439 shares of the medical device company’s stock worth $736,000 after buying an additional 133 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 45,607 shares of the company’s stock in a transaction dated Friday, January 20th. The stock was sold at an average price of $105.75, for a total value of $4,822,940.25. Following the completion of the transaction, the chief executive officer now directly owns 426,645 shares in the company, valued at approximately $45,117,708.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Kevin R. Sayer sold 45,607 shares of the company’s stock in a transaction dated Friday, January 20th. The stock was sold at an average price of $105.75, for a total value of $4,822,940.25. Following the completion of the transaction, the chief executive officer now directly owns 426,645 shares in the company, valued at approximately $45,117,708.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul R. Flynn sold 8,988 shares of the company’s stock in a transaction dated Thursday, December 8th. The stock was sold at an average price of $123.50, for a total value of $1,110,018.00. Following the completion of the transaction, the executive vice president now owns 55,744 shares of the company’s stock, valued at $6,884,384. The disclosure for this sale can be found here. Insiders have sold 57,819 shares of company stock worth $6,294,063 in the last ninety days. 0.41% of the stock is currently owned by insiders.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $106.03 on Wednesday. The firm has a market capitalization of $40.95 billion, a P/E ratio of 195.45, a P/E/G ratio of 2.95 and a beta of 1.14. The company has a quick ratio of 3.43, a current ratio of 3.77 and a debt-to-equity ratio of 1.08. The stock’s 50-day simple moving average is $112.85 and its two-hundred day simple moving average is $99.36. DexCom, Inc. has a twelve month low of $66.89 and a twelve month high of $134.76.

DexCom (NASDAQ:DXCMGet Rating) last announced its earnings results on Thursday, October 27th. The medical device company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. The business had revenue of $769.60 million for the quarter, compared to analyst estimates of $752.67 million. DexCom had a return on equity of 13.27% and a net margin of 8.24%. As a group, equities analysts anticipate that DexCom, Inc. will post 0.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Stifel Nicolaus raised their target price on DexCom from $120.00 to $130.00 in a research report on Tuesday, December 20th. Piper Sandler raised their target price on DexCom to $130.00 in a research report on Tuesday, November 1st. StockNews.com began coverage on DexCom in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Citigroup lifted their price target on DexCom from $117.00 to $146.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Finally, Jefferies Financial Group began coverage on DexCom in a research report on Wednesday, October 12th. They issued a “buy” rating and a $125.00 price target for the company. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $122.00.

DexCom Company Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.